Ferrari, Gerson
Guzmán-Habinger, Juan
Chávez, Javiera L.
Werneck, André O.
Silva, Danilo R.
Kovalskys, Irina
Gómez, Georgina
Rigotti, Attilio
Cortés, Lilia Yadira
Yépez García, Martha Cecilia
Pareja, Rossina G.
Herrera-Cuenca, Marianella
Drenowatz, Clemens
Cristi-Montero, Carlos
Marques, Adilson
Peralta, Miguel
Leme, Ana Carolina B.
Fisberg, Mauro
Funding for this research was provided by:
Coca-Cola Foundation (404905/2016-1)
Article History
Received: 28 May 2021
Accepted: 29 July 2021
First Online: 26 August 2021
Declarations
:
: Not applicable.
: Ethical approval was provided by the Western Institutional Review Board (#20140605), and by the ethical review boards of the participating institutions. ELANS is registered at Clinical Trials #NCT02226627. Written informed consent/assent was obtained from all individuals, before commencement of the study.
: M.F. has received fees and consultancy payments from biotechnology, pharmaceutical and food and beverage companies. He has also received fees, payments for consulting and financing research studies without any restrictions, from government sources and non-profit entities. The rest of the authors also have no conflicts of interest to declare. None of the entities mentioned had or have any role in the design or preparation of this manuscript.